Folate-Engineered Microvesicles for Enhanced Target and Synergistic Therapy toward Breast Cancer

  • ACS Appl Mater Interfaces. 2017 Feb 15;9(6):5100-5108. doi: 10.1021/acsami.6b14633.
Lian Zhu  1 ,  Di Dong  1 ,  Zi-Li Yu  2 ,  Yi-Fang Zhao  2 ,  Dai-Wen Pang  1 ,  Zhi-Ling Zhang  1
Affiliations
  • 1. College of Chemistry and Molecular Sciences, Key Laboratory of Analytical Chemistry for Biology and Medicine (Ministry of Education), Wuhan University , Wuhan 430072, China.
  • 2. School and Hospital of Stomatology, Key Laboratory of Oral Biomedicine (Ministry of Education) and Department of Oral and Maxillofacial Surgery, Wuhan University , Wuhan 430079, China.
PMID: 28106372 DOI: 10.1021/acsami.6b14633
Abstract

As an ideal nanovector candidate, microvesicles (MVs) have been gradually utilized for packaging kinds of Functional Molecules for effective tumor diagnosis and therapy; however, the deficiency of their tumor targeting influenced their therapy efficacy. Through a facile phospholipid substitution strategy, MVs-based drug delivery system (DDS) was apparently endowed with high tumor targeting toward breast Cancer thanks to the modified folate onto the membrane of MVs, simultaneously possessing a synergistic antitumor effect, and in vivo tumor imaging attributed to the SA-QDs labeling. Tumor killing effect could be improved up to 15 percentages with the help of the improved tumor targeting ability.

Keywords
in vivo imaging; microvesicles; phospholipid substitution; synergistic therapy; tumor targeting.
Products